Inspra

Eplerenone, the active ingredient in Inspra, is an aldosterone antagonist presented as an oral tablet for systemic use. It selectively blocks mineralocorticoid receptors, reducing sodium retention and potassium loss, and is indicated for the management of hypertension and for heart failure, especially after myocardial infarction in patients with left ventricular dysfunction.

GNH USA supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide. The product complies with European Union regulatory requirements and is manufactured under GMP conditions.

Eplerenone is used to treat conditions related to excess aldosterone activity, primarily in cardiovascular disease. Hypertension: helps lower blood pressure by antagonizing aldosterone‑mediated sodium retention, leading to reduced fluid volume. Heart failure (post‑myocardial infarction): reduces mortality and hospital readmission by improving cardiac remodeling in patients with left ventricular dysfunction. Left ventricular dysfunction: decreases cardiovascular mortality risk in patients with reduced ejection fraction through neurohormonal modulation.

Eplerenone may be associated with a range of adverse reactions, varying from mild to serious. Common Side Effects: - Hyperkalemia: elevated blood potassium levels. - Dizziness: sensation of lightheadedness. - Headache: mild to moderate head pain. - Fatigue: feeling of tiredness. Serious or Rare Side Effects: - Severe hyperkalemia: potentially life‑threatening potassium rise. - Acute kidney injury: sudden decline in renal function. - Allergic reactions: rash, itching, or angioedema.

When prescribing eplerenone, several safety considerations should be observed. Renal impairment: monitor potassium and creatinine levels regularly. Hyperkalemia risk: avoid concomitant potassium‑sparing diuretics or supplements. Pregnancy: category B, use only if benefit outweighs risk. Elderly patients: start at lower dose and monitor closely. Drug interactions: review concomitant medications for major interactions. Store at ambient temperature: keep below 25 °C, in original container, protect from moisture.

Eplerenone interacts with several drug classes; careful assessment is required. Major Interactions (Avoid): - Potassium‑sparing diuretics (e.g., spironolactone, amiloride): may cause dangerous hyperkalemia. - ACE inhibitors or ARBs: increased risk of hyperkalemia and renal dysfunction. - NSAIDs: can exacerbate renal impairment and potassium retention. Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance antihypertensive effect, monitor blood pressure. - Digoxin: increased serum levels, monitor for toxicity. - Lithium: may increase lithium levels, monitor serum concentration.